Analysis of the US Food and Drug Administration Adverse Events Reporting System between 2015 and 2020 revealed 72 cases of TB and 13 cases of atypical mycobacterial infection due to the use of PD-1/PD-L1 inhibitors [53]. This evidence concerns the gene CD274 and tuberculosis.